Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CG Oncology, Inc.

Latest From CG Oncology, Inc.

Foresite Closes $900m Fund VI As Financial Condition Rebound Begins

Foresite Capital already has invested in multiple high-profile therapeutics firms with its sixth fund, including private Xaira, newly public CG Oncology, and Alumis, which is on the verge of an IPO.

Financing Growth

Rapport Navigates Rough IPO Market With Well-Received Offering

Rapport Therapeutics launched an initial public offering in the middle of a proposed price range, and the CNS-focused company closed slightly above its IPO price on its first day of trading.

Financing Business Strategies

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Approvals ImmunoOncology

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Business Strategies Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Cold Genesys, Inc.